Physician profile
Adam J Brant
NPI 1811998248
$1,246,903.90
in general payments reported to CMS, 2019-2025
11 companies · $144K in 2025
The $144K reported for 2025 was more than what 98% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224K · 2020: $194K · 2021: $184K · 2022: $173K · 2023: $170K · 2024: $157K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $471K · Travel and Lodging: $392 · Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $470,867.64 |
| Travel and Lodging | $392.00 |
| Food and Beverage | $258.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hyhte Holdings INC. | $1,225,672.69 | 2019-2025 | Olympic, Half Dome, Zion |
| Alphatec Spine, INC | $20,345.28 | 2019-2024 | Novel |
| Globus Medical, INC. | $421.11 | 2025 | Excelsius Gps, Magnify, Creo |
| Sanara Medtech INC. | $132.78 | 2025 | Celleraterx |
| Depuy Synthes Sales INC. | $125.00 | 2019 | |
| Smith+Nephew, INC. | $68.28 | 2021-2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5, Renasys Go V2 Home, Renasys Touch |
| Medtronic, INC. | $57.89 | 2021-2023 | Intellis Adaptivestim |
| Baxter Healthcare | $23.87 | 2023 | Floseal |
| Intrinsic Therapeutics | $23.46 | 2025 | Barricaid Acd (Annular Closure Device) |
| Medtronic USA, INC. | $16.87 | 2019 | |
| Nevro Corp. | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Brant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.